Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

CH0432492467
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG00NPWGYJ9
ALC
Alcon AG
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Medical Instruments & Supplies · THEMEFOLIO: $HLTH
NAME
Alcon AG
ISIN
CH0432492467
TICKER
ALC
MIC
XNYS
REUTERS
ALCC.S
BLOOMBERG
ALC US
So., 03.05.2026       Alcon
CH0432492467

Das Instrument 2U3 CH0432492467 ALCON AG NAM. SF -,04 EQUITY wird cum Dividende/Zinsen gehandelt am 04.05.2026 und ex Dividende/Zinsen am 05.05.2026 The instrument 2U3 CH0432492467 ALCON AG NAM. SF -,04 EQUITY has its pre-dividend/interest day on 04.05.2026 and its ex-dividend/interest day on 05.05.2026...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Do., 30.04.2026       Alcon
CH0432492467

Alcon Inc. (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed resolutions at its 2026 Annual General Meeting (“AGM”). A total of 283,222,421 shares with a nominal value of CHF 0.04 each, representing an aggregate nominal value of CHF 11,328,896.84, were represe...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Di., 07.04.2026       Alcon
CH0432492467

This season, Alcon, the global leader in eye care dedicated to helping people see brilliantly, announced that Systane® has partnered with the Toronto Blue Jays as the official eye drop of the team. The partnership aims to help Canadians recognize the signs of dry eye and stay comfortable throughout the game. This press release features multimedia...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Mo., 06.04.2026       Alcon
CH0432492467

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. launch of Clareon® TruPlus, its new enhanced design monofocal and toric intraocular lens (IOL), at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Washington, D.C. TruPlus expands Alcon’s lead...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Do., 02.04.2026       Alcon
CH0432492467

Alcon (SIX/NYSE: ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on April 30, 2026. Alcon is pleased to welcome shareholders to its fourth in-person AGM since becoming an independent, standalone company. The company looks forward to hearing directly from its shareholders at this open format meeting. Alcon's Boar...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Mo., 16.03.2026       Alcon
CH0432492467

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has entered into an agreement with LENSAR, Inc. (NASDAQ: LNSR) to terminate the companies’ previously announced merger agreement. "Alcon continues to believe that the acquisition of LENSAR would have significantly enhanced FL...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Mo., 02.03.2026       Alcon
CH0432492467

Alcon, the global leader in eye care dedicated to helping people see brilliantly, today proudly announced that more than 175 million of its intraocular lenses (IOLs) have been implanted worldwide.9,+ Alcon has more than 30 years of IOL experience with its robust portfolio encompassing the Clareon® and AcrySof® IQ families of IOLs, including Monofo...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Di., 24.02.2026       Alcon
CH0432492467

Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and twelve month periods ending December 31, 2025. For the fourth quarter of 2025, sales were $2.7 billion, up 9% on a reported basis and up 7% on a constant currency basis1, as compared to the same quarter of the previous year. Alcon reported diluted...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Di., 17.02.2026       Alcon
CH0432492467

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. launch of TOTAL30® Multifocal for Astigmatism, the world’s only multifocal toric contact lens with Water Gradient Technology, helping patients stay in lenses comfortably,† as their vision changes from standard correction to ag...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Mo., 02.02.2026       Alcon
CH0432492467

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the Canadian launch of PRECISION7® sphere and toric, the only one-week replacement contact lens with the revolutionary ACTIV-FLO® System2,5 that provides 16 hours of outstanding comfort and precise vision, even on day 7.1 The lenses wi...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Di., 20.01.2026       Alcon
CH0432492467

Alcon Inc., the global leader in eye care dedicated to helping people see brilliantly, today announced the completion of its $750 million share repurchase program, which commenced on April 1, 2025. In aggregate, 9,301,877 registered shares were acquired on the SIX Swiss Exchange, representing 1.9% of the current share capital of Alcon Inc. The t...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Mi., 07.01.2026       Alcon
CH0432492467

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today terminated its definitive merger agreement with STAAR Surgical Company (NASDAQ: STAA) announced on August 5, 2025. “Throughout this process we remained disciplined with our views on price and risk. Moving forward, our refractive strategy is un...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Di., 30.12.2025       Alcon
CH0432492467

Alcon (SIX/NYSE: ALC) CEO David Endicott will present at the 2026 J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 a.m. PST. A live webcast of the conference will be available at investor.alcon.com/news-and-events/events-and-presentations. About Alcon Alcon helps people see brilliantly. As the global leader in eye care...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Mi., 17.12.2025       Alcon
CH0432492467

Expresses Disappointment in the Board's and Management's Continued Pursuit of Ill-advised DealCHARLOTTE, N.C., Dec. 17, 2025 /PRNewswire/ -- Defender Capital ("Defender" or "we"), a long-term shareholder of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA) owning approximately 1.5% of the Company's outstanding common stock, today is...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Di., 09.12.2025       Alcon
CH0432492467

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has entered into an amended merger agreement for the acquisition of STAAR Surgical Company (NASDAQ: STAA, “STAAR”), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision corr...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Di., 11.11.2025       Alcon
CH0432492467

Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and nine month periods ending September 30, 2025. For the third quarter of 2025, sales were $2.6 billion, up 6% on a reported basis and up 5% on a constant currency basis1, as compared to the same quarter of the previous year. Alcon reported diluted e...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Di., 04.11.2025       Alcon
CH0432492467

Alcon (SIX/NYSE: ALC), the global leader in eye care, today announced that it has filed an investor presentation in support of the proposed acquisition of STAAR Surgical Company (NASDAQ: STAA) with the U.S. Securities and Exchange Commission (SEC). Alcon plans to initiate outreach to STAAR stockholders and the presentation highlights key considera...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Di., 07.10.2025       Alcon
CH0432492467

CHARLOTTE, N.C., Oct. 7, 2025 /PRNewswire/ -- Defender Capital ("Defender" or "we"), a long-term shareholder of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA) owning approximately 1.5% of the Company's outstanding common stock, today issued the following statement outlining its opposition of the...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Di., 16.09.2025       Alcon
CH0432492467

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, announced results from time and motion studies demonstrating superior efficiency* with UNITY® Vitreoretinal Cataract System (VCS) for vitreoretinal and cataract surgery compared to CONSTELLATION® Vision System and CENTURION® Vision System with ACTIVE...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Mo., 08.09.2025       Alcon
CH0432492467

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, will present compelling scientific data at the 43rd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) in Copenhagen, Denmark from 12-15 September. During the meeting, Alcon will showcase groundbreaking cataract, refractive a...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Di., 26.08.2025       Alcon
CH0432492467

Alcon (SIX/NYSE: ALC) CEO David Endicott will present at the 2025 Baird Global Healthcare Conference on Tuesday, September 9, 2025, at 9:05 a.m. ET. A live webcast of the conference will be available at investor.alcon.com/news-and-events/events-and-presentations. About Alcon Alcon helps people see brilliantly. As the global leader in eye car...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Di., 19.08.2025       Alcon
CH0432492467

Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and six month periods ending June 30, 2025. For the second quarter of 2025, sales were $2.6 billion, up 4% on a reported basis and up 3% on a constant currency basis1, as compared to the same quarter of the previous year. Alcon reported diluted earnin...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Di., 19.08.2025       Alcon
CH0432492467

Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced a strong presence at the 37th Asia-Pacific Association of Cataract and Refractive Surgeons (APACRS) Annual Meeting. APACRS will be held at Mahatma Mandir Convention and Exhibition Centre (MMCEC) in Ahmedabad, India from August 21-23, 2025. The company...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Di., 22.07.2025       Alcon
CH0432492467

MarketNewsUpdates News Commentary NEW YORK, July 22, 2025 /PRNewswire/ -- According to a report from Research And Markets, the AI in Ophthalmology Market was valued at USD 209.23 million in 2024, and is projected to reach USD 1.36 billion by 2030, rising at a CAGR of 36.79%. The rising prevalence of eye diseases, advancements in imaging technolog...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Di., 22.07.2025       Alcon
CH0432492467

MarketNewsUpdates News Commentary NEW YORK, July 22, 2025 /CNW/ -- According to a report from Research And Markets, the AI in Ophthalmology Market was valued at USD 209.23 million in 2024, and is projected to reach USD 1.36 billion by 2030, rising at a CAGR of 36.79%. The rising prevalence of eye diseases, advancements in imaging technology, and...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Di., 22.07.2025       Alcon
CH0432492467

MarketNewsUpdates News Commentary NEW YORK, July 22, 2025 /PRNewswire/ -- According to a report from Research And Markets, the AI in Ophthalmology Market was valued at USD 209.23 million in 2024, and is projected to reach USD 1.36 billion by 2030, rising at a CAGR of 36.79%. The rising prevalence of eye diseases, advancements in imaging technolog...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Di., 08.07.2025       Alcon
CH0432492467

Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that UNITY® Vitreoretinal Cataract System (VCS) has received Health Canada approval. This innovation is the first to be introduced from Alcon’s highly anticipated Unity portfolio. This press release features multimedia. View the full release here: ht...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Mo., 07.07.2025       Alcon
CH0432492467

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced its intention to acquire LumiThera, Inc., a leader in light-based innovations for ophthalmology, and its PBM device for the treatment of early and intermediate dry AMD.1 LumiThera’s PBM is the only device that has demonstrated meaningf...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Do., 26.06.2025       Alcon
CH0432492467

Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that Alcon Canada has been certified as a Top Employer in Canada by the Top Employers Institute, a recognized authority on identifying excellence in people practices and workplace culture. Being certified as a Top Employer showcases Alcon Canada’s c...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Fr., 20.06.2025       Alcon
CH0432492467

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of Clareon® PanOptix® Pro intraocular lens (IOL) for cataract patients in Canada. PanOptix Pro leverages proprietary ENLIGHTEN® NXT Optical technology which delivers the lowest light scatter and highest reported light util...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Mi., 28.05.2025       Alcon
CH0432492467

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. Food and Drug Administration (FDA) has approved TRYPTYR® (acoltremon ophthalmic solution) 0.003%, formerly known as AR-15512, for the treatment of signs and symptoms of Dry Eye Disease (DED).3 TRYPTYR is a first-in-class TRPM8...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Di., 13.05.2025       Alcon
CH0432492467

Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three months ending March 31, 2025. For the first quarter of 2025, sales were $2.5 billion, flat on a reported basis and up 3% on a constant currency basis1, as compared to the same quarter of the previous year. Alcon reported diluted earnings per share of...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Mo., 12.05.2025       Alcon
CH0432492467

Das Instrument 2U3 CH0432492467 ALCON AG NAM. SF -,04 EQUITY wird ex Dividende/Zinsen gehandelt am 13.05.2025 The instrument 2U3 CH0432492467 ALCON AG NAM. SF -,04 EQUITY has its ex-dividend/interest day on 13.05.2025...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Di., 06.05.2025       Alcon
CH0432492467

Alcon Inc. (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed resolutions at its 2025 Annual General Meeting (“AGM”). A total of 332,704,408 shares with a nominal value of CHF 0.04 each, representing an aggregate nominal value of CHF 13,308,176.32, were represen...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Fr., 25.04.2025       Alcon
CH0432492467

Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced the launch of the UNITY® Vitreoretinal Cataract System (VCS) and UNITY® Cataract System (CS). The new, versatile platform offers two configurations, a combined console (VCS) as well as a standalone cataract system (CS). This platform is designed to de...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Fr., 04.04.2025       Alcon
CH0432492467

Alcon (SIX/NYSE: ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on May 6, 2025. Alcon is pleased to welcome shareholders to its third in-person AGM since becoming an independent, standalone company. The company looks forward to hearing directly from its shareholders at this open format meeting. Alcon's Board of D...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Mi., 02.04.2025       Alcon
CH0432492467

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, announced today the introduction of Clareon® PanOptix® Pro intraocular lens (IOL) for cataract patients in the U.S. PanOptix Pro leverages proprietary ENLIGHTEN® NXT Optical technology which delivers the highest reported light utilization of any trifo...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Mi., 26.03.2025       Alcon
CH0432492467

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has acquired a majority interest in Aurion Biotech, Inc., a clinical-stage company developing advanced cell therapies to treat eye diseases. Aurion will operate as a separate company with full support from Alcon to advance its clin...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Di., 25.03.2025       Alcon
CH0432492467

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that Vivity®, the most widely implanted9 extended depth of focus (EDOF) intraocular lens (IOL), is now available on Alcon’s most advanced lens material—Clareon®.1 Clareon Vivity® received CE Mark and will commence commercial rollout in...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Mo., 24.03.2025       Alcon
CH0432492467

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and LENSAR, Inc. (NASDAQ: LNSR), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced the companies have entered into a definitive merger agreement through which Alcon intends to acqui...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Do., 13.03.2025       Alcon
CH0432492467

Alcon (SIX/NYSE: ALC), the global leader in eye care, will host its 2025 Capital Markets Day on March 27, 2025, beginning at 8:00 a.m. CT. A live webcast of the event will be available at the following link: https://investor.alcon.com/news-and-events/events-and-presentations/event-details/2025/Alcons-2025-Capital-Markets-Day-2025-6w85_Spqte/defau...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Do., 27.02.2025       Alcon
CH0432492467

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the availability of expanded parameters for TOTAL30® for Astigmatism, the first and only monthly replacement Water Gradient toric contact lens,1-3 delivering the same exceptionally comfortable wearing experience,5 now in a –2.75D cylin...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Di., 25.02.2025       Alcon
CH0432492467

Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and twelve month periods ending December 31, 2024. For the fourth quarter of 2024, sales were $2.5 billion, an increase of 6% on a reported and constant currency basis1, as compared to the same quarter of the previous year. Alcon reported diluted earn...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Mo., 24.02.2025       Alcon
CH0432492467

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. launch of SYSTANE® PRO Preservative-Free (PF) as the latest over-the-counter eye drop in the company’s dry eye portfolio. SYSTANE PRO PF is the longest lasting eye drop in the SYSTANE portfolio with a unique triple action, pre...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Mi., 19.02.2025       Alcon
CH0432492467

Alcon (SIX/NYSE: ALC), the global leader in eye care, dedicated to helping people see brilliantly, announced today the full U.S. commercial availability of Voyager™ DSLT, the first and only Direct Selective Laser Trabeculoplasty device (DSLT). Voyager DSLT is uniquely poised to accelerate the adoption of laser as a first-line therapy, unlocking th...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Di., 31.12.2024       Alcon
CH0432492467

Alcon (SIX/NYSE: ALC) CEO David Endicott will present at the 2025 J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 4:30 p.m. PST. A live webcast of the conference will be available at investor.alcon.com/news-and-events/events-and-presentations. About Alcon Alcon helps people see brilliantly. As the global leader in eye care...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Di., 12.11.2024       Alcon
CH0432492467

Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and nine month periods ending September 30, 2024. For the third quarter of 2024, sales were $2.4 billion, an increase of 6% on a reported and constant currency basis1, as compared to the same quarter of the previous year. Alcon reported diluted earnin...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Do., 07.11.2024       Alcon
CH0432492467

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. launch of PRECISION7®, the only one-week replacement contact lens with the revolutionary 7-day ACTIV-FLO® System2 that provides 16 hours of outstanding comfort and precise vision, even on day 7.1 While nearly nine out of ten...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Mo., 28.10.2024       Alcon
CH0432492467

Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that it has been named one of the ‘Best Employers in Singapore’ for the second consecutive year in addition to its recognition in 2021. This prestigious recognition underscores Alcon’s unwavering commitment to building a strong culture of excellence w...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink
Di., 15.10.2024       Alcon
CH0432492467

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, will showcase its latest clinical data and product innovations at the upcoming American Academy of Ophthalmology (AAO) 2024 annual meeting. Ophthalmologists, surgical staff, researchers, and industry leaders can visit Alcon at booth #4008 for hands-on...
Zur Nachricht
Alcon
Charts & Research Termsheets Terminal
Permalink